29 de abril de 2014 / 12:12 / hace 3 años

Biota says to stop developing drug pending contract decision

1 MIN. DE LECTURA

April 29 (Reuters) - Biota Pharmaceuticals Inc said a U.S. agency has asked the company to stop developing its experimental influenza drug, pending a decision related to the company's contract with the agency.

The Biomedical Advanced Research and Development Authority (BARDA) had awarded a contract to the company in 2011 for the development of laninamivir octanoate as a potential treatment for influenza A and B infections. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below